Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →GSK is paying Vir Biotechnology $345 million in upfront and expansion fees to broaden their existing COVID-19 collaboration to influenza and other respiratory…
GSK reported 2021 sales of Xevudy (sotrovimab) of GBP 958 million (~$1.3 billion at constant currency). The product launched in May 2021 under FDA Emergency…
Vir announced that the Phase 2 PENINSULA trial of VIR-2482 for the prevention of seasonal influenza A illness did not meet its primary or key secondary…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
GSK expanded its 2020 collaboration with Vir Biotechnology by paying $120M upfront plus $225M for new respiratory virus programs (~$345M total) to add influenza and other respiratory virus antibody programs alongside the ongoing sotrovimab COVID-19 program with 72.5/27.5 GSK/Vir profit share.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GlaxoSmithKline plc / Vir Biotechnology Inc. (this deal) | 2021 | $345M | — |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| GlaxoSmithKline plc / Tesaro Inc. | 2018 | $5.1B | 79 |
| GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) | 2018 | $12.7B | 76 |
| GlaxoSmithKline plc / Novartis Consumer Healthcare JV | 2018 | $13.0B | 74 |
| GlaxoSmithKline plc / ID Biomedical Corporation | 2005 | $1.4B | 64 |
| GlaxoSmithKline plc / Vir Biotechnology Inc. | 2020 | $595M | 51 |
← Browse all deals · How we score deals
More: 2021 deals · GlaxoSmithKline plc deals · Respiratory deals